Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today reported that it had received revised advice from GlaxoSmithKline (GSK) regarding Relenza sales for the December 2008 quarter. The revised sales were A$27.1 million (US$20.8 million) and indicative royalties were A$1.9 million (US$1.46 million).
Compumedics (ASX:CMP)(PNK:CUPDF) Leading Australian-based medical diagnostic devices company updates the market on its recent activities in the following letter from its Chairman, Mr David Burton.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that GlaxoSmithKline (GSK) has advised of the current Relenza supply situation in respect to the key market of Japan.
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) welcomes news that PRO2000 gel, a candidate microbicide similar to Starpharma's own VivaGel(R), has demonstrated partial effectiveness in preventing HIV infection in women. The study also found that 99% of women in the trial reported that they would use a topical microbicide gel that was approved for HIV prevention.
Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX:BLT)(PINK:BNIKF) announced today that there had been unprecedented interest in the update on the City of Hope HIV trial recently presented in the USA.
The Directors of Benitec Limited (ASX:BLT)(PINK:BNIKF) announced today that it has issued a further 13,222,222 ordinary shares and 13,222,222 unlisted options to its major shareholder following the investment of a further A$595,000 by Dr Christopher Bremner.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received written notification from GlaxoSmithKline (GSK) that Relenza sales were $20.8 million and indicative royalties were $1.46 million, for the three months ended 31 December 2008.
